LEADER 01515nam  2200409 a 450 
001 9910695592703321
005 20070111101528.0
035   $a(CKB)5470000002370839
035   $a(OCoLC)77593544
035   $a(EXLCZ)995470000002370839
100   $a20070111d2006      ua             0
101 0 $aeng
135   $aurmn|---|||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 10$aNew drug development$b[electronic resource] $escience, business, regulatory, and intellectual property issues cited as hampering drug development efforts : report to congressional requesters
210  1$a[Washington, D.C.] :$cU.S. Government Accountability Office,$d[2006]
215   $aii, 47 pages $cdigital, PDF file
300   $aTitle from title screen (viewed on Jan. 10, 2007).
300   $a"November 2006."
300   $aPaper version available from: U.S. Government Accountability Office, 441 G St., NW, Rm. LM, Washington, D.C. 20548.
300   $a"GAO-07-49."
320   $aIncludes bibliographical references.
517   $aNew drug development 
606   $aPharmaceutical industry$xResearch$zUnited States
606   $aDrug development$zUnited States
606   $aDrug approval$zUnited States
615  0$aPharmaceutical industry$xResearch
615  0$aDrug development
615  0$aDrug approval
801  0$bGPO
801  1$bGPO
906   $aBOOK
912   $a9910695592703321
996   $aNew drug development$93545730
997   $aUNINA